HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Relmada Therapeutics

Contributing Author

Recent Articles by Relmada Therapeutics

Mar-19
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update RLMD GlobeNewswire
Mar-12
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 RLMD GlobeNewswire
Mar-09
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference RLMD +61.12% RLMD -7.67% GlobeNewswire
Mar-09
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing RLMD +61.12% GlobeNewswire
Mar-09
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer RLMD +61.12% GlobeNewswire
Jan-12
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications RLMD GlobeNewswire
Dec-03
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology RLMD GlobeNewswire
Nov-13
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates RLMD GlobeNewswire
Nov-07
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 RLMD GlobeNewswire
Nov-04
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants RLMD +25.91% GlobeNewswire
Nov-04
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer RLMD +25.91% GlobeNewswire
Oct-07
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 RLMD GlobeNewswire
Sep-16
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement RLMD GlobeNewswire
Sep-10
Relmada Issues Mid-Year CEO Letter to Shareholders RLMD GlobeNewswire
Aug-07
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC RLMD GlobeNewswire
Jul-31
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 RLMD GlobeNewswire
Jul-15
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 RLMD GlobeNewswire
Jun-17
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology RLMD GlobeNewswire
May-12
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update RLMD -5.05% GlobeNewswire
May-08
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 RLMD +5.64% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)